Wave Life Sciences Ltd. (WVE)
NASDAQ: WVE · Real-Time Price · USD
6.84
-0.42 (-5.72%)
At close: Apr 1, 2026, 4:00 PM EDT
6.98
+0.15 (2.12%)
After-hours: Apr 1, 2026, 4:09 PM EDT
Wave Life Sciences Employees
Wave Life Sciences had 317 employees as of December 31, 2025. The number of employees increased by 29 or 10.07% compared to the previous year.
Employees
317
Change (1Y)
29
Growth (1Y)
10.07%
Revenue / Employee
$134,785
Profits / Employee
-$644,726
Market Cap
1.29B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 317 | 29 | 10.07% | 317 | 0 |
| Dec 31, 2024 | 288 | 20 | 7.46% | 287 | 1 |
| Dec 31, 2023 | 268 | 16 | 6.35% | 266 | 2 |
| Dec 31, 2022 | 252 | 14 | 5.88% | 250 | 2 |
| Dec 31, 2021 | 238 | 18 | 8.18% | 235 | 3 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 711 |
| Biohaven | 274 |
| Precigen | 160 |
| Monte Rosa Therapeutics | 150 |
| Olema Pharmaceuticals | 131 |
| MoonLake Immunotherapeutics | 130 |
| ORIC Pharmaceuticals | 104 |
| AtaiBeckley | 99 |
WVE News
- 4 days ago - Wave Life Sciences Ltd. (WVE) Discusses Positive Interim Phase I Data from INLIGHT Trial of WVE-007 for Obesity Transcript - Seeking Alpha
- 6 days ago - Wave Life Sciences stock crash: why analyst sees a buying opportunity - Invezz
- 6 days ago - Why Is Wave Life Sciences Stock Falling After Weight Loss Study Data? - Benzinga
- 6 days ago - WAVE LIFE SCIENCES Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 6 days ago - Wave Life Sciences shares plunge as data for high dose of obesity drug disappoints - Reuters
- 6 days ago - Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007 - GlobeNewsWire
- 26 days ago - FDA reversals leave investors worrying about the fates of other experimental drugs - CNBC
- 27 days ago - Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference - GlobeNewsWire